Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Trop Med Hyg. 2012 Mar;86(3):434-40. doi: 10.4269/ajtmh.2012.11-0682.

Leishmaniasis in the United States: treatment in 2012.

Author information

  • 1Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA. hwmurray@med.cornell.edu

Abstract

Although civilian physicians in the United States seldom encounter patients with leishmaniasis, therapeutic advances in endemic regions have opened the door to approaches that can be applied in this country. Advances revolve around the use of oral miltefosine in all forms of leishmaniasis and the use of short-course intravenous liposomal amphotericin B in visceral and possibly cutaneous infection. Lengthy, traditional intravenous treatment with pentavalent antimony (sodium stibogluconate) still has a role in the United States; however, although expensive, miltefosine and liposomal amphotericin B are considerably more appealing selections for initial therapy.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk